Zentalis Pharmaceuticals, Inc. (ZNTL) delivered a return of 137.84% over the past year. Since ZNTL does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Zentalis Pharmaceuticals, Inc. one year ago would be worth $23,784 today, representing a gain of $13,784.

Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ZNTL, the total return equals the price-only return.

Yes, Zentalis Pharmaceuticals, Inc. (ZNTL) outperformed the S&P 500 by 115.16 percentage points over the past year. ZNTL delivered a total return of 137.84%, compared to the S&P 500's 22.68%. This 115.16pp alpha means investors in ZNTL earned more than a passive S&P 500 index fund.

Zentalis Pharmaceuticals, Inc. (ZNTL) experienced a maximum drawdown of -46.44% over the past year, declining from its peak on 2026-04-10 to its trough on 2026-06-11. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Zentalis Pharmaceuticals, Inc. (ZNTL)'s long-term returns with dividends reinvested. Over 10 years, the total return is -84.8% (-17.2% CAGR) — $10,000 would have grown to $1,517. Over 20 years: -84.8% total return (-9.0% CAGR) — $10,000 → $1,517. Over 30 years: -84.8% total return (-6.1% CAGR) — $10,000 → $1,517. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Zentalis Pharmaceuticals, Inc.'s best calendar year was 2020 with a total return of 123.9%. Its worst year was 2024 with a total return of -81.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 204.9 percentage points.